查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968153

全球胜肽類藥物偶聯物市場規模、佔有率、趨勢及成長分析報告（2026-2034年）

Global Peptide Drug Conjugates Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

胜肽類藥物偶聯物市場預計將從 2025 年的 12.6 億美元成長到 2034 年的 66.3 億美元，2026 年至 2034 年的複合年成長率為 20.23%。

隨著旨在提高治療效果的標靶藥物遞送系統研究不斷深入，全球胜肽-藥物偶聯物市場正快速成長。肽-藥物偶聯物可將胜肽與活性藥物分子結合，提高治療精準度並減少副作用。這種方法在癌症治療和其他慢性疾病領域正日益受到關注。

成長要素包括癌症病例增加、標靶治療研究進展以及生物技術進步。由於胜肽類療法具有高特異性且優異的患者療效，製藥公司正大力投資開發此類療法。臨床試驗的增加以及生物技術公司與研究機構之間的合作也推動了市場擴張。

未來，藥物偶聯技術的持續創新以及應用領域在腫瘤學以外的拓展，將推動市場成長。隨著人們對更安全、更有效治療方法的需求日益成長，胜肽類藥物偶聯物有望在下一代治療中發揮關鍵作用，從而帶來強勁的長期成長前景。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球胜肽類藥物偶聯物市場：依產品分類

  • 市場分析、洞察與預測
  • 鎦
  • 美洛芬
  • ANG1005
  • BT1718
  • CBX-12
  • 其他正在研發中的產品

第5章 全球胜肽類藥物偶聯物市場：按類型分類

  • 市場分析、洞察與預測
  • 治療性胜肽藥物複合物
  • 診斷胜肽藥物偶聯物

第6章 全球胜肽類藥物偶聯物市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Novartis AG
    • Oncopeptides AB
    • Bicycle Therapeutics
    • AstraZeneca
    • Cybrexa Therapeutics
    • Angiochem Inc
    • Innovasium Soricimed Biopharma
    • Theratechnologies
    • Coherent Biopharma
    • WuXI STA
簡介目錄
Product Code: VMR112110347

The Peptide Drug Conjugates Market size is expected to reach USD 6.63 Billion in 2034 from USD 1.26 Billion (2025) growing at a CAGR of 20.23% during 2026-2034.

The Global Peptide Drug Conjugates Market is growing rapidly as researchers explore targeted drug delivery systems for improved therapeutic outcomes. Peptide drug conjugates combine peptides with active drug molecules to enhance precision and reduce side effects. This approach is gaining popularity in cancer treatment and other chronic diseases.

Growth drivers include rising cancer cases, increasing research in targeted therapies, and advancements in biotechnology. Pharmaceutical companies are investing heavily in developing peptide-based therapeutics due to their high specificity and better patient outcomes. Growing clinical trials and collaborations between biotech firms and research institutes are also supporting market expansion.

In the future, continued innovation in drug conjugation technologies and expanding applications beyond oncology will drive market growth. As demand for safer and more effective treatments increases, peptide drug conjugates are expected to play a key role in next-generation therapies, ensuring strong long-term prospects.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

  • Lutetium
  • Melflufen
  • ANG1005
  • BT1718
  • CBX-12
  • Other Pipeline Products

By Type

  • Therapeutic Peptide Drug Conjugates
  • Diagnostic Peptide Drug Conjugates

COMPANIES PROFILED

  • Novartis AG, Oncopeptides AB, Bicycle Therapeutics, AstraZeneca, Cybrexa Therapeutics, Angiochem Inc, Innovasium Soricimed Biopharma, Theratechnologies, Coherent Biopharma, WuXI STA
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Lutetium Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Melflufen Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. ANG1005 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. BT1718 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. CBX-12 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Other Pipeline Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PEPTIDE DRUG CONJUGATES MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Therapeutic Peptide Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnostic Peptide Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PEPTIDE DRUG CONJUGATES MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Product
    • 6.2.2 By Type
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Product
    • 6.3.2 By Type
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Product
    • 6.4.2 By Type
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Product
    • 6.5.2 By Type
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Product
    • 6.6.2 By Type
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PEPTIDE DRUG CONJUGATES INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Novartis AG
    • 8.2.2 Oncopeptides AB
    • 8.2.3 Bicycle Therapeutics
    • 8.2.4 AstraZeneca
    • 8.2.5 Cybrexa Therapeutics
    • 8.2.6 Angiochem Inc
    • 8.2.7 Innovasium Soricimed Biopharma
    • 8.2.8 Theratechnologies
    • 8.2.9 Coherent Biopharma
    • 8.2.10 WuXI STA